Form 4 Filing for HENDERSON JOHN T

This filing details a transaction by HENDERSON JOHN T, a director at CYTOKINETICS INC. On April 15, 2026, 325 shares of Common Stock were acquired under the Director Equity in Lieu of Cash Retainer Program, with a transaction price of $65.37 per share. These shares are fully vested. Following this acquisition, the post-transaction number of shares held directly is 75,237. Additionally, 83 shares of Common Stock are held indirectly and are owned by the reporting owner's spouse.